Impact of COVID-19 on tuberculosis services: an experience from a tertiary care hospital

Jamwal, Ashima; Mohanty, Ankita; Swami, Anjali; Turbadkar, Dilip

doi:10.1099/jmm.0.001559

Cited by 2 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…India is reported to have the highest burden of TB globally, with 2.4 million cases reported in the National TB Program of India in 2019 8 . It is possible that some patients with TB were not notified or management was interrupted due to the diversion of the medical workforce to COVID‐19 services 9 . During the past 2 years, India has been affected simultaneously by COVID‐19, TB, and DM (henceforth termed as TB‐DM; “syndemic”), and although COVID‐19 has potentially waned, TB and DM continue unabated.…”

Section: Introductionmentioning

confidence: 99%

Diabetes and tuberculosis syndemic in India: A narrative review of facts, gaps in care and challenges

Vaishya

Misra

Vaish

et al. 2023

Journal of Diabetes

View full text Add to dashboard Cite

Both diabetes mellitus (DM) and tuberculosis (TB) are prevalent all across in India. TB‐DM comorbidity has emerged as a syndemic and needs more attention in India considering gaps in screening, clinical care, and research. This paper is intended to review published literature on TB and DM in India to understand the burden of the dual epidemic and its trajectory and to obtain perspectives on the gaps, constraints, and challenges in care and treatment of this dual epidemic. A literature search was carried out on PubMed, Scopus, and Google Scholar, using the key words ‘Tuberculosis’ OR ‘TB’ AND ‘Diabetes’ OR ‘Diabetes Mellitus’ AND ‘India’, focusing on the research published between the year 2000 to 2022. The prevalence of DM is high in patients with TB. Quantitative data on the epidemiological situation of TB/DM in India such as incidence, prevalence, mortality, and management are lacking. During the last 2 years convergence of TB‐DM syndemic with the COVID‐19 pandemic has increased cases with uncontrolled DM but also made coordinated control of TB‐DM operationally difficult and of low effectiveness. Research regarding TB‐DM comorbidity is required in the context of epidemiology and management. Detection and bidirectional screening are aggressively warranted. Management of DM in those with TB‐DM comorbidity needs more efforts, including training and supervision of frontline workers.

show abstract

Section: Introductionmentioning

confidence: 99%

Diabetes and tuberculosis syndemic in India: A narrative review of facts, gaps in care and challenges

Vaishya

Misra

Vaish

et al. 2023

Journal of Diabetes

View full text Add to dashboard Cite

show abstract

The impact of the COVID-19 pandemic on tuberculosis treatment outcomes in 49 high burden countries

Gunsaru,

Henrion,

McQuaid

2024

BMC Med

View full text Add to dashboard Cite

Background The COVID-19 pandemic disrupted tuberculosis (TB) health services, including treatment support and access to drugs, as patients were not able to access health facilities. While the effect of this disruption on treatment outcomes has been studied in isolated treatment centres, cities and provinces, the impact of the pandemic on TB treatment outcomes at a country and regional level has not been evaluated. Methods We used treatment outcomes for new and relapse TB cases reported to the World Health Organization (WHO) from 49 high TB, TB/HIV and drug-resistant TB burden countries from 2012 to 2019. We developed multinomial logistic regression models for trends in TB treatment success, failure, death and loss to follow up. We predicted TB treatment outcomes for 2020 and 2021, comparing these to observations, by computing ratios between observed and predicted probabilities. We aggregated these risk ratios (RR) for six WHO-defined regions using random-effects meta-analysis. Results Across 49 countries and four TB treatment outcomes, 17 (out of 196) country-outcome pairs in 2020 and 21 in 2021 had evidence of systematic differences between observed and predicted TB treatment outcome probabilities. Regionally, only four (out of 24) region-outcome pairs had evidence of systematic differences in 2020 and four in 2021, where the European region accounted for four of these in total. Globally, there was evidence of systematic differences in treatment failure in both 2020 (RR: 1.14, 95%CI: 1.01–1.28, p = 0.0381) and 2021 (RR: 1.36, 95%CI: 1.03–1.78, p = 0.0277), deaths in 2020 (RR: 1.08, 95%CI: 1.03–1.13, p = 0.0010) and losses to follow up in 2020 (RR: 0.91, 95%CI: 0.86–0.97, p = 0.0059). Conclusions While for some countries and regions there were significant differences between observed and predicted treatment outcomes probabilities, there was insufficient evidence globally to identify systematic differences between observed and expected TB treatment outcome probabilities because of COVID-19-associated disruptions in general. However, larger numbers of treatment failures and deaths on treatment than expected were observed globally, suggesting a need for further investigation.

show abstract

Impact of COVID-19 on tuberculosis services: an experience from a tertiary care hospital

Cited by 2 publications

References 18 publications

Diabetes and tuberculosis syndemic in India: A narrative review of facts, gaps in care and challenges

Diabetes and tuberculosis syndemic in India: A narrative review of facts, gaps in care and challenges

The impact of the COVID-19 pandemic on tuberculosis treatment outcomes in 49 high burden countries

Contact Info

Product

Resources

About